Your browser doesn't support javascript.
loading
Nationwide Coverage and Cost-Sharing for PCSK9 Inhibitors Among Medicare Part D Plans.
Kazi, Dhruv S; Lu, Christine Y; Lin, Grace A; DeJong, Colette; Dudley, R Adams; Chen, Randi; Tseng, Chien-Wen.
Affiliation
  • Kazi DS; Division of Cardiology at Zuckerberg San Francisco General Hospital, University of California, San Francisco.
  • Lu CY; Department of Population Medicine, Harvard Medical School, Boston, Massachusetts.
  • Lin GA; Harvard Pilgrim Health Care Institute, Boston, Massachusetts.
  • DeJong C; Center for Healthcare Value, Philip R. Lee Institute for Health Policy Studies, University of California, San Francisco.
  • Dudley RA; Center for Healthcare Value, Philip R. Lee Institute for Health Policy Studies, University of California, San Francisco.
  • Chen R; Center for Healthcare Value, Philip R. Lee Institute for Health Policy Studies, University of California, San Francisco.
  • Tseng CW; Pacific Health Research and Education Institute, Honolulu, Hawaii.
JAMA Cardiol ; 2(10): 1164-1166, 2017 10 01.
Article in En | MEDLINE | ID: mdl-28903137
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: PCSK9 Inhibitors / Antibodies, Monoclonal / Anticholesteremic Agents Type of study: Health_economic_evaluation Limits: Adult / Humans Country/Region as subject: America do norte Language: En Journal: JAMA Cardiol Year: 2017 Document type: Article
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: PCSK9 Inhibitors / Antibodies, Monoclonal / Anticholesteremic Agents Type of study: Health_economic_evaluation Limits: Adult / Humans Country/Region as subject: America do norte Language: En Journal: JAMA Cardiol Year: 2017 Document type: Article